Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL14889298 | 0.90 | TAAR1 (0.42) | TAAR1LTA4HPLA2G2AKDM4EMAPK1 | |
| SCHEMBL5961239 | 0.81 | KCNA3 (0.35) | TAAR1LTA4HALDH1A1TSHRKCNA3 | |
| SCHEMBL28480364 | 0.80 | KDM4E (0.46) | TAAR1LTA4HPLA2G2AKDM4EMAPK1 | |
| SCHEMBL465983 | 0.80 | TAAR1 (0.54) | TAAR1LTA4HPLA2G2AKDM4EMAPK1 | |
| SCHEMBL6660834 | 0.78 | TAAR1 (0.52) | TAAR1LTA4HPLA2G2AKDM4EMAPK1 | |
| SCHEMBL28022149 | 0.72 | KDM4E (0.64) | TAAR1LTA4HPLA2G2AKDM4EMAPK1 | |
| SCHEMBL2278236 | 0.71 | TAAR1 (0.52) | TAAR1LTA4HPLA2G2AKDM4EMAPK1 | |
| SCHEMBL51246 | 0.71 | LTA4H (0.50) | TAAR1LTA4HALDH1A1ALOX15TSHR | |
| SCHEMBL5370837 | 0.70 | MAPK1 (0.47) | TAAR1LTA4HPLA2G2AKDM4EMAPK1 | |
| SCHEMBL1554318 | 0.69 | HRH1 (0.46) | TAAR1LTA4HPLA2G2AKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056896-A | Application of 2-aminoethoxy diphenyl borate in preparation of medicine for preventing and/or treating gout | 安徽医科大学第二附属医院 | 2026-05-19 | — | — | CN | claimed |
| US-20240197867-A1 | NEURAL CONTROL OF ADAPTIVE IMMUNITY | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2024-06-20 | — | — | US | claimed |
| WO-2024033113-A1 | ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN REGULATION OF SKIN PIGMENTATION | CUTANEON - SKIN & HAIR INNOVATIONS GMBH (DE) | 2024-02-15 | — | — | WO | claimed |
| US-20240050455-A1 | METHODS OF TREATMENT OF A CYTOKINE STORM | LOMA LINDA UNIV HEALTH (US) | 2024-02-15 | — | — | US | claimed |
| EP-4321148-A1 | ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN REGULATION OF SKIN PIGMENTATION | CUTANEON - Skin & Hair Innovations GmbH (DE) | 2024-02-14 | — | — | EP | claimed |
| CN-116981449-A | Compounds and compositions for inducing neuroprotection | 瑞斯特医疗公司 | 2023-10-31 | — | — | CN | claimed |
| EP-4142703-B1 | COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTION | REST THERAPEUTICS (FR) | 2023-10-18 | — | — | EP | claimed |
| WO-2023196235-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2023196234-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | claimed |
| US-20230310380-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-05 | — | — | US | claimed |
| US-20050059092-A1 | Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation | BLANCHETTE ROCKEFELLER NEURSOCIENCES INSTITUTE (US) | 2005-03-17 | — | — | US | claimed |
| CN-1549721-A | Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation | ����Ъ����˷���� �ѧ�о��� | 2004-11-24 | — | — | CN | claimed |
| EP-1385531-A4 | ALZHEIMER'S DISEASE DIAGNOSIS BASED ON MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHORYLATION | BRNI NEUROSCIENCES INST (US) | 2004-05-12 | — | — | EP | claimed |
| EP-1385531-A2 | ALZHEIMER'S DISEASE DIAGNOSIS BASED ON MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHORYLATION | Blanchette Rockefeller Neurosciences Institute (US) | 2004-02-04 | — | — | EP | claimed |
| EP-1331932-A2 | THERAPEUTIC USES FOR IP 3? RECEPTOR-MEDIATED CALCIUM CHANNEL MODULATORS | Contrimmune Biotechnology Inc. (CA) | 2003-08-06 | — | — | EP | claimed |
| WO-2002067764-A3 | ALZHEIMER'S DISEASE DIAGNOSIS BASED ON MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHORYLATION | BRNI NEUROSCIENCES INST (US) | 2002-11-14 | — | — | WO | claimed |
| WO-2002067764-A2 | ALZHEIMER'S DISEASE DIAGNOSIS BASED ON MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHORYLATION | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2002-09-06 | — | — | WO | claimed |
| US-20020107193-A1 | Therapeutic uses for IP3 receptor-mediated calcium channel modulators | CONTRIMMUNE BIOTECHNOLOGY INC. (CA) | 2002-08-08 | — | — | US | claimed |
| WO-2002059155-A2 | MODULATION OF CALCIUM CHANNEL ACTIVITY | UNIVERSITY OF LEEDS (GB) | 2002-08-01 | — | — | WO | claimed |
| WO-2002038140-A2 | THERAPEUTIC USES FOR IP3 RECEPTOR-MEDIATED CALCIUM CHANNEL MODULATORS | CONTRIMMUNE BIOTECHNOLOGY INC (CA) | 2002-05-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197867-A1 | NEURAL CONTROL OF ADAPTIVE IMMUNITY | TRPV1, TRPA1, TRPV2 | TAAR1 889/4885LTA4H 293/4885PLA2G2A 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.